Novo Nordisk (B): The PrandinNovonorm Global Product Launch Harvard Case Solution & Analysis

FDA believes that Prandin was a very innovative product that provides fast growing number of Americans suffering from type II diabetes with better and more convenient for the treatment of health problems. For this reason, FDA has been willing to put Prandin applications on the fast track, which will allow Novo Nordisk, to have a registered product (making it legal to sell) to a maximum of 6 months. The decision to conduct an initial worldwide launch Prandin / Novonorm in the United States in a very short period of time is not easy. "Hide
by Joel Podolny, John Roberts, Aldo Kemper Source: Stanford Graduate School of Business 16 pages. Publication Date: July 10, 2000. Prod. #: IB20B-PDF-ENG

Novo Nordisk (B): The PrandinNovonorm Global Product Launch Case Solution Other Similar Case Solutions like

Novo Nordisk (B): The PrandinNovonorm Global Product Launch

Share This